
A French biotech company presented encouraging data this week from early trials of a vaccine that aims to stop tumours recurring in cancer patients.
Transgene, a company based in the eastern French city of Strasbourg, says results from a phase I clinical trial of its cancer vaccine suggest it can produce an immune response that helps stop new tumours growing.